Within the first year of life, the CDC recommends that children receive a total of 29 vaccinations, many of which contain the adjuvant aluminum, a substance used in vaccinations to increase the immune response to the antigen (the component of the vaccine that stimulates the immune system to make antibodies). 
According to Professor Christopher Exley’s recent research, there are currently two main aluminum adjuvants commonly used in vaccinations today. These are AlHydrogel, a semi-crystalline (boehmite) form of aluminium oxyhydroxide and AdjuPhos, an amorphous salt of aluminium hydroxyphosphate. The sulphate salt of the latter is also listed as being one component of an adjuvant system used in vaccinations against HPV. AlHydrogel™ and AdjuPhos™ are commonly referred to as clinically-approved aluminum adjuvants, and yet this is not the case.
There are no aluminum adjuvants that have been approved for intramuscular or subcutaneous injection into humans. There are no requirements for their approval; they are only “approved” as part of vaccine preparations.